Group 1 - The core point of the article is that Kewang Pharmaceutical (002737) has reported a total of 49,000 shareholders as of December 19 [1]

一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 40,000 万元购买了部分理财 产品，具体情况如下： | 序 | 签约机构 | 产品名称 | 产品类型 | 金额 | 起息日 | 到期日 | 预期年化收 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | （万元） | | | 益率 | 来源 | | | 招商银行 | 招银理财招睿和鼎 | 固定收益类 | | | | | 闲置 | | 1 | 哈尔滨平 | 高评级封闭179号固 | 非保本浮动 | 40,000.00 | 2025.12.16 | 2026.03.27 | 1.90%-2.20% | 自有 | | | 房支行 | 定收益类理财计划 | 收益型 | | | | | 资金 | | | | 合计 | | 40,000.00 | | | | | 注：公司与上述签约机构不存在关联关系。 证券代码：002737 证券简称：葵花药业 公告编号：2025-081 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本 ...

Core Viewpoint - The announcement from the Heilongjiang Provincial Drug Administration confirms that Heilongjiang Sunflower Pharmaceutical Co., Ltd. has successfully passed the GAP compliance inspection for traditional Chinese medicine materials, indicating adherence to quality management standards [3]. Group 1: Compliance and Inspection Results - The inspection was conducted from November 25 to November 27, 2025, and the results showed compliance with GAP requirements [3]. - The inspection covered various traditional Chinese medicine products, including liver protection tablets and children's cough syrup, with specific details on product specifications and geographical coordinates of the production bases [3]. Group 2: Product Specifications - The liver protection tablets have a specification of 0.35g per tablet, while the children's cough syrup is equivalent to 1.77g of herbal slices per milliliter [3]. - The children's cough granules are specified at 3g per bag, all of which are registered under national drug standards [3].

证券日报网讯12月15日，葵花药业（002737）在互动平台回答投资者提问时表示，截至12月10日，公司 股东人数为5.1万户。 ...

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector experienced a significant decline, with the Chinese medicine index dropping by 2.03% last week, while other pharmaceutical sub-sectors also faced declines, except for medical services which saw a 1.67% increase [1][19] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.17X, down by 0.55X week-on-week, while the price-to-book (PB) ratio is 2.29X, down by 0.04X week-on-week [2] - The demand for flu-related and tonic herbs has increased, leading to a rise in the price index of Chinese medicinal materials, which is expected to continue to rise slightly in the future [3] - The national medical insurance work conference highlighted the restructuring of prices and market patterns as a major direction for the Chinese medicine industry in 2026, emphasizing the importance of collective procurement and support for innovation in the industry [4][9] Summary by Sections Market Performance - The Chinese medicine index closed at 6372.09 points, down 2.03% last week, with only the medical services sector recording positive returns [1][19] Valuation - The current PE ratio for the Chinese medicine sector is 27.17X, with a year-high of 30.26X and a year-low of 24.72X, placing it at the 28.41% percentile since 2013 [2] Supply Chain Insights - The price index for Chinese medicinal materials rose to 225.57 points, a 0.4% increase from the previous week, driven by increased demand due to the flu outbreak and winter tonic herbs [3] Policy and Market Trends - The 2026 direction for the Chinese medicine industry includes continued promotion of collective procurement and support for innovation, with an emphasis on price governance and market restructuring [4][10] - The focus on long-term care insurance is expected to increase demand for Chinese medicine products, particularly in the context of an aging population [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, with specific recommendations for companies with strong R&D capabilities and unique products [10][11]

Core Points - The establishment of the "Influenza Drug Supply and Price Stability Alliance" aims to ensure sufficient supply and stable prices for influenza-related medications and protective supplies in response to the high prevalence of influenza across 17 provinces in China [1][3] - The alliance includes 25 well-known domestic and international pharmaceutical companies, and it will leverage JD's instant retail network to meet market demand for flu-related products [3][4] - JD has committed to resisting unreasonable price increases and will implement strict price monitoring and management for flu-related medications and protective supplies [3][4] Group 1 - The influenza-like illness detection positivity rate has reached 51%, with expectations for a peak in mid-December [1] - The alliance covers a full range of flu treatment products, including prescription drugs, OTC medications, masks, and disinfectant gels [3] - JD will enhance delivery capabilities, ensuring rapid delivery of medications, with the fastest delivery time being 9 minutes [3] Group 2 - The initiative includes a customer care aspect, with a program offering complimentary warm water with orders in select cities until March 2026 [3] - The comprehensive response system focuses on drug supply assurance, price stability, rapid delivery, and humanistic care [4] - JD aims to collaborate with upstream and downstream partners in the industry to help the public navigate the flu season smoothly [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002737 证券简称：葵花药业 公告编号：2025-080 葵花药业集团股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 表决结果：同意9票，反对 0 票，弃权 0 票，通过。 本事项属董事会审议权限，无需提交股东会审议。 三、备查文件 1、公司第五届董事会第十四次会议决议 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事会第十四次会议于2025年12月9 日上午9时以通讯表决方式召开。会议由公司董事长关玉秀女士召集，会议通知及议案于2025年12月4日 通过电子邮件形式发出。 会议应参加表决董事9人，实际参加表决董事9人。本次会议召集、召开程序符合《公司法》及相关法 律、法规以及《公司章程》之规定。会议决议合法有效。 二、董事会会议审议情况 1、审议通过《关于对外捐赠的议案》 针对秋冬季节流感频发态势，为积极履行社会责任，实效践行"产业报国、贡献社会、受益员工、回报 股东"之核心价值观，公司决定向无关联关系的地 ...

Group 1 - The core viewpoint of the news is that Kew Flower Pharmaceutical (SZ 002737) held its 14th meeting of the 5th Board of Directors on December 9, 2025, via telecommunication to discuss proposals including external donations [1] - For the first half of 2025, Kew Flower Pharmaceutical's revenue composition shows that the pharmaceutical industry accounts for 99.61%, while other businesses account for 0.39% [1] - As of the report date, Kew Flower Pharmaceutical has a market capitalization of 8.5 billion yuan [2]

格隆汇12月9日丨葵花药业(002737.SZ)公布，针对秋冬季节流感频发态势，为积极履行社会责任，实效 践行"产业报国、贡献社会、受益员工、回报股东"之核心价值观，公司决定向无关联关系的地方社会公 益组织捐赠价值不超过1,000万元的医药类产品及物资（含下属各控股公司捐赠），具体捐赠事宜授权 公司经营管理层根据各地实际需求办理实施。 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-080 葵花药业集团股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、审议通过《关于对外捐赠的议案》 针对秋冬季节流感频发态势，为积极履行社会责任，实效践行"产业报国、 贡献社会、受益员工、回报股东"之核心价值观，公司决定向无关联关系的地方 社会公益组织捐赠价值不超过 1,000 万元的医药类产品及物资（含下属各控股公 司捐赠），具体捐赠事宜授权公司经营管理层根据各地实际需求办理实施。 本次捐赠不构成关联交易，不构成《上市公司重大资产重组管理办法》规定 的重大资产重组，不会对公司生产、经营产生重大影响。 1 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过。 本事项属董事会审议权限，无需提交股东会审议。 三、备查文件 1、公司第五届董事会第十四次会议决议 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十四次会议于 2025 年 12 月 9 日上午 9 时以通讯表决方式召开。会议由公司 董事 ...